Immune responses play an important part in maintaining homeostasis and normal physiological functions. Abnormal activity of immune cells either over reactivity leading to the destruction of tissues or excessive inflammation or underactivity leading to failure of recognising and fighting danger signals leading to immune-mediated diseases. Several factors including risk factors may play a part in disease development, progress, and therapy. Some examples of immune-mediated diseases are autoimmune diseases such as multiple sclerosis, Systemic Lupus, Type 1 Diabetes, Rheumatoid arthritis, Allergies, and cancer.
Since the discovery of CD4+CD25+ tTreg 32 years ago, it is now well established that tTreg plays an essential role in homeostasis, particularly in protecting the host from self-destructive, over-aggressive immune response and in other immune responses such as organ graft outcome and graft versus host disease. The immunosuppressive effect of tTreg, their mechanism of action and therapeutic effects have been extensively studied in many immune-mediated diseases including autoimmunity, GVHD, tumour therapy, and allergy. Clinical trials have demonstrated the safety of the administration of ex-vivo expanded Treg, but their efficacy is not proven although reduced acute and chronic GVHD in bone marrow transplants and safety in Type-1 diabetes are reported. With the demonstration of heterogeneity within the Treg pool coming into focus, several Treg types including activated Treg may have different roles in immune-mediated disease.
The objective of this research topic is to provide a comprehensive collection of research papers dealing with the role of T regulatory cells in immune-mediated diseases, their mechanism of action, and their therapeutic potential in these diseases.
This research topic aims to cover the following:
1. Association of Treg with immune-mediated diseases
2. Mechanism of action of Treg in immune-mediated diseases
3. Therapeutic effect of Treg in immune-mediated disease.
4. Treg subtypes in immune-mediated diseases
Original research articles and review papers that increase our understanding of the role of this cell population in immune-mediated diseases are welcome.
Immune responses play an important part in maintaining homeostasis and normal physiological functions. Abnormal activity of immune cells either over reactivity leading to the destruction of tissues or excessive inflammation or underactivity leading to failure of recognising and fighting danger signals leading to immune-mediated diseases. Several factors including risk factors may play a part in disease development, progress, and therapy. Some examples of immune-mediated diseases are autoimmune diseases such as multiple sclerosis, Systemic Lupus, Type 1 Diabetes, Rheumatoid arthritis, Allergies, and cancer.
Since the discovery of CD4+CD25+ tTreg 32 years ago, it is now well established that tTreg plays an essential role in homeostasis, particularly in protecting the host from self-destructive, over-aggressive immune response and in other immune responses such as organ graft outcome and graft versus host disease. The immunosuppressive effect of tTreg, their mechanism of action and therapeutic effects have been extensively studied in many immune-mediated diseases including autoimmunity, GVHD, tumour therapy, and allergy. Clinical trials have demonstrated the safety of the administration of ex-vivo expanded Treg, but their efficacy is not proven although reduced acute and chronic GVHD in bone marrow transplants and safety in Type-1 diabetes are reported. With the demonstration of heterogeneity within the Treg pool coming into focus, several Treg types including activated Treg may have different roles in immune-mediated disease.
The objective of this research topic is to provide a comprehensive collection of research papers dealing with the role of T regulatory cells in immune-mediated diseases, their mechanism of action, and their therapeutic potential in these diseases.
This research topic aims to cover the following:
1. Association of Treg with immune-mediated diseases
2. Mechanism of action of Treg in immune-mediated diseases
3. Therapeutic effect of Treg in immune-mediated disease.
4. Treg subtypes in immune-mediated diseases
Original research articles and review papers that increase our understanding of the role of this cell population in immune-mediated diseases are welcome.
